As part of our series focussing on medicines in Australia, we have added a product review of the use of andexanet alfa for reversal of anticoagulation in adult patients treated with apixaban or rivaroxaban. This review summarises the pharmacological and clinical characteristics of andexanet alfa and efficacy and tolerability through clinical trials and real-world evidence.
Commentary is provided by Professor Ken Butcher, Medical Director of New South Wales’ Telestroke Service and Deputy Head of Campus at the School of Clinical Medicine, Randwick, University of New South Wales.
Please login below to download this issue (PDF)